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Background/aim: Polycythemia Vera (PV) is a myeloproliferative disorder characterized by overproduction of
morphologically normal red blood cells (RBCs), granulocytes, and platelets, a phenotype that is caused by a mutation
(V617F) in Janus kinase 2 (JAK2). However, JAK2 V617F is also found in approximately 50% of patients with essential
thrombocytosis and primary myelofibrosis, rendering its presence nonspecific as a diagnostic test. An increased red cell
mass is a major criterion for the diagnosis of PV according to World Health Organization (WHO) 2016 criteria. High
hemoglobin (Hgb) or Hematocrit (Hct) are universally used as indicators of an increased red cell mass for the diagnosis
of PV. However, conditions such as iron deficiency (ID) with decreased mean cell volume may mask the diagnosis due to
nonelevated Hct level. The aim of this study was to investigate the clinical characteristics of the patients with unclassifiable
non-CML classical myeloproliferative disease with microcytosis (MPD/M) and nonelevated Hgb and Hct levels at diagnosis
and to determine if some of these cases could be real PV cases masked due to ID-related microcytosis.
Materials and methods: There were 23 MPD/M cases among 208 non-CML classical MPD cases (11%). Among 22 patients
who had adequate test results related to the cause of microcytosis, ID and beta-thalassemia trait (TT) were the apparent
causes of microcytosis in 15 and 1 cases, respectively.
Results: Clinicopathological correlations revealed consistently positive JAK2 V617F mutation status (20/20, 100%),
frequently elevated RBC count (17/23, 73.9%), and PV-compatible bone marrow findings (10/12, 83.3%). These findings
are compatible with PV instead of essential thrombocytopenia or primary myelofibrosis. In spite of frequent cytoreductive
treatment, 3 patients developed increased Hgb/Htc levels during median 58.2 (279–63) months’ follow-up.
Conclusion: These data show that the majority of MPD/M cases are PV patients masked due to ID-related microcytosis.
Key words: Polycythemia, microcytosis, myeloproliferative, iron deficiency
1. Introduction
Myeloproliferative neoplasms (MPN) is a group of diseases
associated with erythroid and myeloid cell proliferation
leading to bone marrow hypercellularity, resulting in
erythrocytosis, leukocytosis, and thrombocytosis in
the peripheral blood [1]. The diagnosis of classical
Philadelphia-negative myeloproliferative diseases (MPD)
may represent a challenge for clinicians. Polycythemia vera
(PV) is a myeloproliferative neoplasm with erythrocytosis
predominance [2]. Radionuclide assessment is the historical
gold standard method for the determination of total red
blood cell mass (TRCM) [3]. Hematocrit (Htc) and/or

hemoglobin (Hgb) values have long been recommended for
the diagnosis of polycythemia vera (PV) since the World
Health Organization (WHO) 2001 criteria mainly due to
limitations of the radionuclide test [2,4]. High hemoglobin
(Hgb) (>16 g/dL in females and 16.5 g/dL in males) or
hematocrit (Hct) (>48% in females and >49% in males) are
universally used as indicators of an increased red cell mass
for the diagnosis of PV [2]. Hgb and Htc, as concentration
values, may fail to reflect absolute erythrocytosis and
increased TRCM in the case of hypervolemia/increased
splenic sequestration (for instance, Budd Chiari syndrome
(BCS)) and also in cases of concurrent microcytosis [5].
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The aim of this study was to assess the clinical
characteristics of the patients with MPD/M and not elevated
Hgb and Htc levels at presentation. We hypothesized that
many of those cases (to be mentioned as MPD/M from
this point on) were true PV cases masked by microcytosis.
2. Materials and methods
In our outpatient clinic at the Department of Hematology,
Faculty of Medicine of Hacettepe University, ET, PMF,
PV, and unclassifiable non-CML classical MPD patients
diagnosed in 2003–2018 and with adequate electronical,
clinical, and laboratory data were screened retrospectively.
The MPD patients with deficient complete blood count
test parameters at presentation were excluded. Patients
could have been diagnosed with a MPD within 12 months
before admission to our center. However, the patients who
had received any cytotoxic/antiproliferative therapy were
also excluded. The original diagnoses were presumably
established depending on the universal diagnostic criteria
valid at the time of presentation [6]. For this study elevated
Hgb and Htc were accepted the same as WHO 2016 levels
for the diagnosis of PV, i.e. 16 g/dL and 48% for women
and 16.5 g/dL and 49% for men. An elevated red blood
cell (RBC) count was accepted as >5.4 × 106/L and >6.0 ×
106/L for females and males, respectively [2]. Microcytosis
was defined as a mean cell volume lower than 80 fL. The
patients with microcytosis (and not elevated Hgb/Htc
values) at presentation were closely evaluated for all of the
clinical and laboratory data also including the etiology of
microcytosis, treatment modalities, disease course, and
complications. Iron deficiency (ID) was accepted in case
of a transferrin saturation (TS) <15% associated with a
ferritin level <30 ng/mL. The ferritin cut-off level for iron
deficiency was defined as 50 ng/mL in case of associated
acute phase response and/or liver dysfunction. Highnormal (>375 mcg/dL) or elevated (>450 mcg/dL) total
iron binding capacity was also required for these patients
with a ferritin level between 30 and 50 ng/mL [6,7].
Laboratory investigations were performed at Hacettepe
University’s Clinical Biochemistry and Experimental
Oncology Laboratories. Transferrin saturation was
computed by dividing serum iron level by total iron
binding capacity. For analysis the JAK2 V617F mutation,
genomic DNA extracted from the peripheral blood of
the patients and DNA samples were tested with PCR and
gel detection method (NuSieve 3:1 agarose/TBE gel) was
used for amplification (InVivoScribe Technologies, San
Diego, CA, USA). Bone marrow aspiration and biopsy
specimens had been reported by experienced University
staff hematopathologists and they were reevaluated by
one of the authors considering current MPD marrow
diagnostic criteria for the purpose of this study. Bone
marrow findings were evaluated considering WHO

diagnostic criteria for differential diagnosis of MPDs [8,9].
Bone marrow biopsy showing hypercellularity for age with
trilineage growth (panmyelosis) including prominent
erythroid, granulocytic, and megakaryocytic proliferation
with pleomorphic, mature megakaryocytes (differences in
size) was considered compatible with PV [8].
Data were presented as proportions or medians
(minimum-maximum) for categorical and continuous
variables, respectively. Categorical variables were compared
using chi-square or Fisher’s exact tests and continuous
variables were compared using Student’s t-test or Mann–
Whitney U test. Statistical analyses were performed using
SPSS (IBM Inc., Armonk, NY, USA) software versions 23.
This study was approved by Hacettepe University
Ethical Board on 02.07.2019 with the approval number of
GO 19672.
3. Results
There were 23 MPD with M cases among 208 non-CML
classical MPD cases (11%) suitable for evaluation. Among
22 patients who had adequate test results related to the
cause of microcytosis, ID and beta-thalassemia trait (TT)
were the apparent causes of microcytosis in 15 and 1 cases,
respectively. One patient had both iron deficiency and TT.
Among 5 out of 22 patients without iron deficiency and/or
TT 2 patients had clearly hypoferremia (a TS lower than
15%) and one patients had a borderline TS level (15.2%).
Only 2 patients had clearly normal serum iron test results.
Demographic and clinical characteristics are summarized
in Table. All of 20 patients with available JAK2 V617F
mutation test result had JAK2 V617F positivity. Nine of 23
MPD with M patients had an elevated red blood cell count

Table. Demographic and clinical characteristics of the MPD
patients with microcytosis and normal Hgb/Hct levels at
diagnosis.
Mean
(± standard deviation)
Age (years)

55.9 (±11.7)

Hemoglobin (g/dL)

12.4 (±1.9)

Hematocrit (%)

38.8 (±5.5)

Red blood cell (× 10 /L)

5.4 (±0.86)

Platelet (× 103/L)

579.3(±377.4)

6

White blood cell (× 10 /L)
3

11.8 (±6.1)
(n) (%)

Female/male

15/8 (65.2/34.8)

Iron deficiency (yes/no/unknown)

16/6 (69.5/26)

JAK2 V617F mutation (yes/unknown) 20/3 (86.9/13.1)
Splenomegaly (yes/no)

14/9 (60.8/39.2)
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at diagnosis. Serum erythropoietin level was available in
10 patients. It was decreased in 6 patients. Bone marrow
biopsy was available in 18 MPD with M cases. After
reevaluations bone marrow biopsy samples were found
sufficient for MPD differential diagnosis in 12 patients.
None of them were compatible with ET. PV and PMF were
the possible diagnoses in 10 and 2 patients, respectively.
Twenty-one patients received cytoreductive treatment
(19 hydroxyurea, 1 pegylated interferon alpha-2a, and 1
thalidomide and ruxolitinib) after presentation. In spite
of treatment, at a median follow-up of 31.5 (0–131.6)
months, 3 out of 23 MPD with M patients developed
elevated Hgb and/or Htc levels compatible with PV
WHO 2016 diagnostic criteria either with or without iron
supplementation. Eight out of 14 patients with normal
RBC at diagnosis developed an increased red blood
cell count. Only 6 patients did not show any lab sign
indicating increased red blood cell production neither
at diagnosis nor during disease course. Five of them had
a suitable bone marrow biopsy specimen. The histology
was compatible with PMF in 2 out of 5 patients.
Regarding important clinical complications;
thromboembolism, hemorrhage, and transformation
to myelodysplastic syndrome occurred in 9 (39,1%),
1 (4,3%), and 1 (4.3%), respectively, of the patients at a
median follow-up duration of 2.4 months (0–15) after
the presentation. All patients were still alive at the last
contact.
4. Discussion
The results of our study demonstrated that MPD/M
patients may actually have PV masked due to associated
ID and microcytosis. Clinicopathological correlations
revealed consistently positive JAK2 V617F mutation
status (20/20, 100%), frequently elevated RBC count
(17/23, 73.9%), and PV-compatible bone marrow
findings (10/12, 83.3%). These findings are compatible
with PV instead of ET or PMF. Thrombohemorrhagic
problems (9/23, 39.1%) are also more compatible with

the diagnosis of PV [7]. In spite of frequent cytoreductive
use 3 patients developed increased Hgb/Htc levels during
median 58.2 (279–63) months’ follow-up.
It is clear that Hgb and Htc levels are suitable
laboratory parameters reflecting TRCM in the absence
of radionuclide TRCM testing [10]. However, these two
routine blood parameters may be masked by two frequent
complications of PV; hemodilution (as in BCS) and IDrelated hypochromia/microcytosis. For such patients,
WHO 2016 criteria proposed another alternative
parameter for the determination of erythrocytosis:
an increased red cell mass 25% above mean normal
predicted value [1]. Although it may be useful in some
cases, such as BCS patients with masked PV, this proposal
is practically futile as this test is very rarely available. It is
quite surprising that RBC count (which is not masked at
least by ID-related hypochromia/microcytosis) had not
previously been proposed as a diagnostic parameter in any
established PV diagnostic criteria. Ideally the estimation
power of RBC count in the differential diagnosis should
be prospectively investigated in a larger cohort including
various masked PV cases. Bone marrow biopsy may also
be another guide in the differential diagnosis of the MPD
with M cases, although there are contradictory study
results regarding the reproducibility of bone marrow
morphological features for the diagnosis of PV.
Currently, the MPD/M cases are usually followed as
“unable to classify” in everyday clinical practice. Based on
our present data, however, they should they be followed
as true PV. This approach may have therapeutic impact
in some cases as it has been confirmed that keeping Htc
level below 45% with phlebotomy, hydroxyurea, or both
decreases cardiovascular death and major thrombosis
compared to a Htc target of 45% to 50% in PV [11].
In conclusion; in our study, the findings showed that
the majority of MPD/M cases were PV patients masked
due to ID related microcytosis. This clinical condition
should be kept in mind in the diagnosis and treatment of
patients with non-CML MPD.
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